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Abstract
Objective: Individuals with Down syndrome (DS) have an extremely high
genetic risk for Alzheimer’s disease (AD), however, the course of cognitive
decline associated with progression to dementia is ill-defined. Data-driven
methods can estimate long-term trends from cross-sectional data while adjust-
ing for variability in baseline ability, which complicates dementia assessment in
those with DS. Methods: We applied an event-based model to cognitive test
data and informant-rated questionnaire data from 283 adults with DS (the lar-
gest study of cognitive functioning in DS to date) to estimate the sequence of
cognitive decline and individuals’ disease stage. Results: Decline in tests of
memory, sustained attention/motor coordination, and verbal fluency occurred
early, demonstrating that AD in DS follows a similar pattern of change to other
forms of AD. Later decline was found for informant measures. Using the result-
ing staging model, we showed that adults with a clinical diagnosis of dementia
and those with APOE 3:4 or 4:4 genotype were significantly more likely to be
staged later, suggesting that the model is valid. Interpretation: Our results
identify tests of memory and sustained attention may be particularly useful
measures to track decline in the preclinical/prodromal stages of AD in DS
whereas informant-measures may be useful in later stages (i.e. during conver-
sion into dementia, or postdiagnosis). These results have implications for the
selection of outcome measures of treatment trials to delay or prevent cognitive
decline due to AD in DS. As clinical diagnoses are generally made late into AD
progression, early assessment is essential.
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Introduction
Down syndrome (DS) is due to full or partial trisomy,
translocation, or mosaicism of chromosome 21, and is
associated with intellectual disability (ID).1 DS is also a
genetic cause of Alzheimer’s disease (AD), largely due to
triplication of the amyloid precursor protein (APP) gene
at 21q21.3.2–4 AD neuropathology is universally present
in adults with DS from their fourth decade,5,6 driving an
elevated risk for dementia due to AD that is estimated to
reach 80% by age 65,7 though the age of clinical dementia
onset shows large variability.8 The age of onset for
dementia in DS is similar to that in familial AD due to
mutations in the known AD causing genes - APP, prese-
nilin 1 (PSEN1) and presenilin 2 (PSEN2),9 with mean
age of diagnosis around 55, and an interquartile range of
approximately 50–59 years of age.8 However, unlike
familial AD, the sequence and course of dementia in DS
is less well-described, despite this population currently
accounting for the majority of genetic AD cases.
In individuals with DS, the development of dementia
needs to be understood in the context of a complex cog-
nitive phenotype that not only includes general ID, but
also specific impairments in executive function, memory,
language, and motor domains.10,11 Such pre-existing
impairments in those with DS need to be distinguished
from subsequent decline, and in combination with vary-
ing baseline abilities and limitations in speech abilities
can make the interpretation of cognitive test data, and
thus clinical diagnosis, difficult.12,13
The evaluation of longitudinal change suggestive of AD
in DS, within and across different cognitive domains,
poses significant challenges. In addition to the aforemen-
tioned difficulties of assessing decline in the presence of
varying degrees of premorbid ID, it is not trivial to
understand the long-term longitudinal progression of a
disease when the majority of studies sample populations
at different stages of disease progression, by taking cross-
sectional or short-term longitudinal measurements.14
Data-driven methods have become a valuable tool for
studying long-term disease progression due to their ability
to estimate long-term trends from cross-sectional and
short-term longitudinal snapshots of cohorts, and can be
adjusted for variability in baseline ability. The event-based
model (EBM) is one such method capable of estimating
orderings of multimodal measurements and staging par-
ticipants.15 The EBM has been applied previously to neu-
roimaging, cerebrospinal fluid (CSF), and cognitive
markers in sporadic AD,16 and more recently was refor-
mulated to model more complex cognitive datasets in
young onset AD and posterior cortical atrophy.17
The aim of this work was to characterize the cognitive
deterioration associated with the development of AD in
DS. We applied the data-driven EBM to markers of cog-
nitive and informant-rated ability of individuals with DS
to estimate the order of cognitive decline and assign par-
ticipants to a disease stage. We further aimed to deter-
mine the effect of a clinical diagnosis of dementia and
APOE genotype on stage, given that APOE genotype is
strongly associated with age of onset of dementia due to
AD, with the e4 allele driving earlier onset and increased
risk and the e2 allele reducing risk.18
Methods
Ethics and consent
We obtained ethical approval from the National Health
Service Research Ethics Committee for the LonDownS
consortium’s longitudinal study of cognitive ability in DS,
including approval for collection of DNA samples (13/
WA/0194). Individuals with capacity to consent for them-
selves provided written informed consent, and for those
who did not have decision-making capacity, a consultee
was approached to indicate their agreement to the indi-
vidual’s participation, in accordance with the UK Mental
Capacity Act 2005.
Participants
We recruited individuals with a clinical diagnosis of DS
aged 16 years and older living in family homes and resi-
dential facilities across England and Wales via a volunteer
database, support groups, and local National Health Ser-
vice (NHS) Trust sites. Participants with any acute physi-
cal or mental health condition were excluded from
participation until they had recovered.
Due to the increased risk of people with DS developing
AD neuropathology characterized by amyloid deposition
beyond age 35 as demonstrated by neuropathological and
amyloid positron emission tomography studies,2,19,20 we
used age 35 to split participants into two age groups. The
young adult (YA) group, aged 16–35, were likely perform-
ing at or near to their cognitive peak, while the older
adult (OA) group, aged 36 and older, were expected to
have AD neuropathology with individuals presenting with
varying degree of cognitive decline. We therefore defined
the YA group as a predecline “control” group, while the
OA group was used as a “pathological” group in the
model due to the likelihood that many of the OA group
have already undergone cognitive deterioration, whether
they have been diagnosed with dementia or not. This
approach was chosen because we wished to identify the
stages of cognitive decline associated with prodromal AD
in DS leading up to clinical dementia diagnosis. In subse-
quent analyses, we used dementia status to test the
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validity of the model. The semisupervised mixture model-
ing technique used (Event-based model) has been previ-
ously shown to be capable of discerning splits from
heterogeneous inputs, such as the YA and OA groups in
this work.
Cognitive test battery
We selected tests and outcomes from the LonDownS cog-
nitive battery that showed good psychometric properties
across the age groups:
1 General cognitive abilities were assessed using raw
scores from the verbal and nonverbal subscales of the
Kaufman Brief Intelligence Test 2 (KBIT-2).21
2 Visuospatial associate memory was assessed with the
first trial memory score from the CANTAB paired
associates learning (PAL) task.22 This sums the num-
ber of pattern positions correctly recalled after their
first presentation in all stages attempted.
3 Object memory was assessed using an adapted form of
the Fuld object memory test.23 This task provides mea-
sures of immediate and 5-min delayed memory recall.
4 Orientation abilities were assessed by asking partici-
pants questions about when it was (the day, month,
and year), and where they were.24
5 The intra/extra dimensional set shift (IED) task is a
measure of rule learning and set shifting from the
CANTAB.22 Here, we used the total number of stages
completed.
6 An adapted version of the Tower of London for indi-
viduals with an ID assessed working memory and
planning.11,25
7 To measure semantic verbal fluency participants were
asked to name as many animals as possible in 1 min.
8 The mean latency of responses in the simple reaction
time (SRT) task from the CANTAB was used as a
measure of attention and motor abilities.22,26
9 The finger-nose pointing test is a clinical measure of
motor coordination.27
10 The car and motorbike score from the NEPSY-II – visuo-
motor precision task assesses hand-eye coordination.28
Informants (relatives or paid carers) completed stan-
dardized questionnaires. These included:
1 The Short Adaptive Behavior Scale (short ABS),29
adapted from the Adaptive Behavior Scale – Residential
and Community (Part I),30 records participants’ every-
day adaptive abilities.
2 The Dementia Questionnaire for People with Learning
Disabilities (DLD) measures behaviors associated with cog-
nitive decline in people with ID over the last two months.31
Cognitive and social domains scores were included.
3 The Observer Memory Questionnaire (OMQ) measures
individuals’ memory abilities over the last 2 months
We developed a revised, shorter version, by selecting
the most reliable items appropriate for use in adults with
ID.32
Further information about the LonDownS participants,
cognitive assessments, and informant questionnaires can
be found in (Startin et al. 201611), with a summary of
tests and outcomes used in Table 1.
Imputation
Floor effects and difficulty to engage in cognitive tasks are
a significant issue in studies of cognitive decline in indi-
viduals with DS, and excluding those who score at floor
or who do not engage could significantly bias analyses.
We therefore imputed scores as follows: individuals who
attempted tasks but were clearly unable to understand
task instructions were allocated a score of zero for out-
comes aside from SRT mean latency, where the poorest
score recorded was given. Missing items from the DLD
and OMQ were imputed for up to 15% of items within
each domain with the nearest integer to the mean value
of completed scores.
ID severity score
Premorbid ID level was defined according to the ICD10
diagnostic system, and classified into three levels based on
caregiver’s reports of the individual’s best ever level of
functioning - mild, moderate, and severe ID, correspond-
ing to the general functional abilities associated with IQ
levels of 50–69, 35–49, and <35, respectively, as described
elsewhere.33
Dementia diagnoses
Dementia diagnoses were used to test the validity of the
staging model, and were defined as the presence of an
existing, independent clinical diagnosis from each individ-
ual’s clinician after comprehensive clinical assessment.
Clinical diagnosis has previously been shown to be reli-
able.34 None of the tests used in the EBM were used to
inform diagnoses.
Genetic analysis
Participants’ DS status was confirmed genetically using saliva
or blood samples where possible; following DNA extraction,
genome-wide single nucleotide polymorphism (SNP) geno-
typing was performed using an Illumina OmniExpressEx-
ome array (San Diego, CA) at UCL Genomics, then
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assembled and visually inspected in GenomeStudio to con-
firm the presence of an additional copy of chromosome 21,
mosaicism, or translocation. APOE genotype was deter-
mined using a Thermo Fisher Scientific Taqman assay for
SNPs rs7412 and rs429358 (Waltham, MA).
Event-based model
Scores from the cognitive tests and informant question-
naires, controlled for ID level, were used as input in the
EBM, with scores termed as ‘biomarkers’ for the
remainder of this paper, for brevity and to be consistent
with previous descriptions of the model.15,16 Unimodal,
two-component, nonparametric mixture models were fit
for each of the biomarkers, these models were then used
to assign probabilities PðxjEiÞ and Pðxj:EiÞ of a biomar-
ker measurement, x, being abnormal (event Ei has
occurred) or normal (Ei has not occurred) that is the
measurement indicating dementia or not respectively.17
The OA and YA groups were used to define the initial
components in each mixture model, by defining each
group as a component and then fitting kernel density
Table 1. Summary of assessments used.










Subtests assess participants’ verbal
abilities (verbal knowledge and riddles)
and nonverbal abilities (matrices)







Participants were required to remember
locations of an increasing number of




Object memory test Recall memory Participants were required to name
and remember a series of objects, then
recall them in two immediate trials and
one 5 min delayed trial
Immediate recall (0–14);
Delayed recall (0–7)
CAMCOG orientation Orientation Assesses participants’ knowledge of







Participants were required to learn rules
about which was the ‘correct’ of two
presented patterns on a computer screen,




Tower of London Working memory
and planning
Participants were required to move
beads on a board to match presented
configurations.
Total score (0–10)
Verbal fluency Semantic verbal fluency Participants were asked to name as





Attention/motor abilities Participants were required to press a button
as soon as a white square appeared on a
computer screen
Mean latency (N/A)
Finger-nose pointing Motor coordination Participants alternatively touch their nose
and a red circle 45 cm away for 20 sec





Hand-eye coordination Participants were timed as they traced
around train, car, and motorbike tracks,
with times and number of errors for each
















Informants answer questions about
behaviors associated with cognitive decline





Memory Informants answer questions about
individuals’ memory abilities over the
last 2 months
Total score (18–90)
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estimations to each group separately. The fitting proce-
dure then uses these initial components to estimate two
components corresponding to a dementia and nonde-
mentia subpopulation. This is possible as mixture mod-
eling is a semisupervised method capable of learning
underlying patterns in the data that correspond to
dementia or not, despite being only provided with the
YA and OA labels. The EBM was then used to estimate
the maximum likelihood ordering of events. In this work
the ordering of events corresponds to the order of
decline on cognitive tests and informant questionnaires,
which transition outside of a premorbid range due to
cognitive decline associated with AD progression. The
EBM was used as previously described,35 briefly an event
sequence S, was optimized using Markov chain Monte
Carlo (MCMC) sampling to maximize the probability of
the full set of data, X (all biomarkers from all individu-
als), given by











  !" #
(1)
where i 2 I is the biomarker index and j 2 J is the partic-
ipant number. The fitting procedure identifies the maxi-
mum likelihood sequence S^, from which disease stages
were estimated for individuals given their test scores. Sim-
ilar to previous descriptions of the EBM (e.g.16), we used
the stage, kj, which has the highest probability given the
data and our sequence, i.e.










Disease stages for adults in the OA and YA groups were
then compared, as were stages of adults in the OA group
with and without a clinical diagnosis of dementia, and
stages for individuals with different APOE genotypes for
the YA and OA groups separately. The APOE4 group was
defined as those possessing a copy of the APOE e4 allele
(APOE 3:4 and 4:4), while the APOE2 group included
individuals possessing a copy of the APOE e2 allele
(APOE 2:2 and 2:3), and the APOE3 group consisted of
those possessing two copies of the APOE e3 allele (APOE
3:3). Individuals with APOE 2:4 genotype were omitted
from this analysis. All group comparisons used Mann–
Whitney U tests.
Results
This analysis included 283 participants, with details of
participants included in the study summarized in
Table 2.
Event sequences
To account for the severity of cognitive deficits not
caused by dementia development but instead due to the
intellectual impairments associated with DS, ID level was
used to estimate residuals in the YA group for each bio-
marker using linear regression coefficients, then these
coefficients were used to calculate residuals for all individ-
uals’ biomarker measurements. An EBM was fit using the
YA and OA groups as control and disease populations,
respectively, and a maximum likelihood event sequence
was obtained together with sampling uncertainty
(Fig. 1A). As this method is Bayesian we did not directly
estimate significance, instead a stricter estimate of uncer-
tainty in the maximum likelihood event sequence was
estimated by bootstrap resampling of the data and refit-
ting the model 100 times (Fig. 1B).
The resulting event sequence implicates decline in visu-
ospatial associate memory (measured using the CANTAB
PAL first trial memory score), hand-eye coordination (us-
ing the NEPSY-II car/motorbike score), and semantic ver-
bal fluency as early events associated with the likely
development of significant AD neuropathology in older
adults with DS. Although these tasks cover different cog-
nitive domains, they all rely on sustained attention to
perform well, indicating a common underlying ability.
Tests of object memory and planning/rule learning such
as the Tower of London defined midsequence events,
while late events were defined by informant-rated scales
of everyday function and cognitive ability (DLD, short
ABS, and revised OMQ; Fig. 1A). Bootstrapping shows a
high degree of certainty in the event sequence (Fig. 1B).
Staging
Using the maximum-likelihood event sequence a disease
stage was assigned to each participant. The distribution of
stages in the YA and OA groups (Fig. 2) show that the
YA group is significantly more likely to be at the earlier
stages of the disease (U = 4489.5, p < 0.001). The OA
group, which was assumed to all have some degree of AD
neuropathology, shows a spread along the event stages.
As the disease population used in this model (i.e. the
OA group) consists of individuals who do not have a
clinical diagnosis of dementia, we further analysed the
stages of the OA group comparing those with and with-
out clinical dementia diagnoses (Fig. 3). From this we see
that individuals with a clinical diagnosis of dementia are
significantly more likely to be staged later according the
EBM (U = 743, p < 0.001).
Splitting individuals based on APOE genotype, we saw
no relationship with disease stage in the YA group
(Fig. 4A), however, in the OA group we observed that
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individuals in the APOE4 group were significantly more
likely to be staged later according to the EBM compared
to both the APOE2 (U = 205.5, p < 0.002) and APOE3
(U = 950, p < 0.001) groups (Fig. 4B).
Discussion
Using data from nearly 300 adults with DS, we have
applied an EBM to characterize the sequence of AD-
related cognitive deterioration in DS. Our estimated event
ordering represents the first AD progression model of this
type in DS, a population at exceptionally high genetic risk
of developing dementia and representing the majority of
genetic AD cases. Results suggest decline in visuospatial
paired associate memory, hand-eye coordination, and
semantic verbal fluency may be relatively sensitive events
during the prodromal stage of AD in DS. Changes in
planning abilities and rule learning/shifting may occur
slightly later, while changes in informant-rated behaviors
and abilities appeared latest in the model. These results
suggest that direct cognitive tests may be more sensitive
to early changes than informant-rated questionnaires.
This highlights the need for baseline cognitive assessments
in this population to enable early intervention, as subtle
changes in cognitive tests may be seen before carers iden-
tify decline. The staging distribution of individuals with
clinical dementia diagnoses provides validity to the
model, and suggests that clinical diagnoses are generally
made at a relatively late stage of AD progression in DS.
As additional validation of the model, we showed that
older individuals with APOE 3:4 or 4:4 genotype were
more likely to be allocated to later disease stages than
those not possessing an APOE e4 allele.
As with sporadic AD, in DS there is a time lag of up to
several decades between the development of AD neu-
ropathology and meeting the threshold for clinical
dementia diagnosis.2,36,37 Memory decline, particularly for
episodic memory, is viewed as the classic presenting
symptom of AD, which gradually progresses to involve
other cognitive domains.38 However, studies of familial
Table 2. Demographic data and mean (SD) neuropsychological scores for younger adult and older adult groups.
Younger adults Older adults
Participants n 119 164
DS status confirmed n = 115 n = 156
110 trisomy 150 trisomy
1 translocation 1 translocation
3 mosaic 5 mosaic
1 partial trisomy
Age 25.24 (5.58) 49.58 (7.47)***
Gender 57 M; 62 F 87 M; 77 F
LD level 45 mild; 63 moderate; 11 severe 69 mild; 67 moderate; 28 severe
Clinical dementia status 119 no dementia 121 no dementia; 43 dementia
APOE genotype n = 111 n = 151
n = 19 APOE 2:2 or 2:3 n = 22 APOE 2:2 or 2:3
n = 60 APOE 3:3 n = 90 APOE 3:3
n = 31 APOE 3:4 or 4:4 n = 35 APOE 3:4 or 4:4
n = 1 APOE 2:4 n = 4 APOE 2:4
Tests KBIT-2 raw verbal n = 119; 34.95 (16.99) n = 164; 23.02 (18.77)***
KBIT-2 raw non-verbal n = 119; 15.00 (6.94) n = 154; 9.78 (7.43)***
PAL first trial memory n = 107; 10.19 (5.67) n = 144; 4.53 (5.61)***
IED stages complete n = 108; 6.52 (2.59) n = 144; 3.41 (3.06)***
SRT mean latency n = 104; 695.72 (455.97) n = 137; 1423.08 (793.61)***
Delayed object memory n = 109; 5.78 (1.52) n = 151; 3.60 (2.66)***
Immediate object memory n = 109; 10.26 (3.00) n = 151; 6.41 (4.75)***
NEPSY car motorbike score n = 116; 17.12 (9.56) n = 151; 8.05 (8.91)***
Tower of London n = 113; 7.24 (3.12) n = 155; 4.41 (3.97)***
Finger nose n = 114; 11.02 (5.25) n = 155; 6.09 (5.48)***
Verbal fluency n = 115; 10.81 (5.91) n = 157; 6.10 (5.92)***
Orientation n = 113; 9.55 (3.56) n = 155; 6.52 (4.71)***
DLD cognitive n = 111; 7.57 (8.35) n = 140; 15.68 (12.75)***
DLD social n = 114; 9.31 (6.87) n = 143; 14.66 (10.52)***
Short ABS total n = 114; 79.60 (19.46) n = 144; 64.79 (27.00)***
OMQ revised n = 116; 43.42 (12.31) n = 141; 56.38 (17.16)***
Significant differences between groups have been highlighted, p < 0.005 (***).
746 ª 2018 Crown copyright. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Alzheimer’s Disease in Down Syndrome N. C. Firth et al.
AD mutation carriers have found that some individuals
show decline in measures of sustained attention, executive
function, language, or behavior several years prior to
dementia diagnosis,39–41 suggesting the sequence of
changes we have shown in our population with DS is
comparable to that seen in other genetic AD populations.
Previous EBM models have shown that in sporadic AD,
changes in cognitive abilities, including memory and
attention, follow changes in CSF biomarkers, but occur
before brain volumetric changes.16,42 The cognitive tests
used in these models have tended to combine several cog-
nitive processes. Here, by including tests for more specific
cognitive processes as separate biomarkers, we can look
more closely at the sequence of decline in populations
where obtaining CSF biomarkers, for example, may be
challenging.
It has been suggested that executive function decline
and behavioral and personality changes may precede
memory impairment in dementia development in DS,43,44
with some studies reporting that individuals with DS may
present with a frontal-like dementia syndrome in the ear-
liest stages.43,45 A recent systematic review of longitudinal
DS studies drew similar conclusions,46 however, large
variability in the follow-up period and cognitive tasks
used prevented a meta-analysis, and several of the studies
included found, like us, that memory and spatial orienta-
tion decline seemed to happen first.47–49
Test sensitivity is a key challenge when assessing base-
line cognition and subsequent decline in DS, and may
explain these apparently conflicting findings. Some of the
studies in the previously mentioned review relied on
informant report, which our model suggests may be less
sensitive to early change than direct cognitive assessment.
Figure 1. Positional variance diagrams show the maximum likelihood event sequence. Each entry represents the proportion of samples with each
biomarker in each position ranging from 0 in white to 1 in black. (A) Positional variance diagram of the Markov chain Monte Carlo samples
generated during fitting of the event-based model (B) diagram of the samples generated during bootstrapping of the model.
Figure 2. Histogram of event-based model stages for all participants,
colored by age group.
Figure 3. Histogram of event-based model stages for old adult
participants, colored by clinical diagnosis.
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Furthermore, Lautarescu and colleagues highlighted that
those with a standardized IQ < 40 had very low scores on
the memory tasks used, regardless of their dementia sta-
tus. The CANTAB PAL and object memory tasks used in
our battery (but none of the reviewed studies) allowed us
to assess visuospatial memory and immediate and delayed
recall of everyday items in the majority of our sample,
with fewer than 1% of our younger adults aged 16–35
(including many with IQ < 40) at floor on delayed object
memory trials,11 suggesting that these specific tests are
suitable for those with DS and can identify decline in this
population. However, for the object memory task, 40% of
our younger adults were scoring at ceiling for the delayed
object memory trial, suggesting this test may be insuffi-
ciently sensitive for measuring ability changes in those
with comparatively strong premorbid delayed object
memory. Future studies should perhaps increase the num-
ber of objects used to improve sensitivity.
The sequence of events revealed by our model has
important clinical implications, and suggests that tests of
visuospatial associate memory, hand-eye coordination, and
verbal fluency may be particularly useful to track early, sub-
tle cognitive change in middle-aged individuals with DS in
the preclinical and prodromal stages of AD. These tests
may all have decline in sustained attention in common,
indicating this may be another important aspect of cogni-
tion to track changes. The model also suggests that infor-
mant-reported measures may be more useful somewhat
later in the course of progression in the lead-up to demen-
tia diagnosis, and to monitor progression after diagnosis.
AD staging based on EBM could help clinicians track
decline during the early stages of cognitive decline in DS,
and enable earlier diagnosis that might be beneficial by
allowing for timely care-planning and support. It could
also be of use to distinguish a typical sequence of events
associated with AD development from the reversible
decline that might be due to other, treatable,
comorbidities, such as depression or hypothyroidism.
Equally promising is the potential use of this model to
enable AD staging in clinical trials to select appropriate
participants with DS for particular trials, for example
those designed to prevent or delay onset of dementia in
the prodromal stages. It might also be possible to use
such models in the analysis of clinical trial data, by com-
paring different treatments or placebo controls in terms
of progression along the stages of the model. However,
we acknowledge that data from further longitudinal stud-
ies may be required to confirm and refine the staging
model for these applications. Due to the flexibility of the
model we can confirm our staging model by using fol-
low-up data in the model independently, and also by
staging patient’s follow-up scores and checking the mono-
tonicity of patients EBM stage trajectories.
This analysis is based on one of the largest and most
detailed studies of cognitive decline in DS to date. Partici-
pants completed a battery of cognitive tests, which were
specifically designed to cover domains commonly affected
by DS, including aspects of memory, motor coordination,
and executive functions. The tests were adapted to be
suitable for use in individuals with DS and selected to
minimize reliance on verbal ability, a known area of
weakness in individuals with DS. Tests were validated in
older adults with DS50 before being applied in a large
sample including both younger and older adults with DS
which allowed for selection of tests with acceptable floor
and ceiling effects.11 However, we acknowledge the lack
of tasks specifically focusing on verbal memory, which is
often one of the earliest domains affected in AD.
By using an innovative approach and designating older
adults with DS as likely being along a decline trajectory
regardless of dementia status, it allowed us to provide a
more complete picture of the sequence of events associ-
ated with the progression of AD in DS than has been pos-
sible to date. Furthermore, the EBM methodology allows
Figure 4. Histogram of event-based model stages colored by APOE genotype. (A) Young adults (B) Old adults.
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for inclusion of individuals who had floored on some
tests, which is usually a major limitation to cognitive test-
ing in older individuals with DS.10
In conclusion, we have used a data driven approach to
overcome some of the common issues in analysis of cog-
nitive data in individuals with DS, and our results reveal
that the sequence of events in the progression of AD in
DS is comparable to events during the development of
AD in other populations, including those with autosomal
dominant AD. Specifically, the event sequence suggests
that early decline in memory and sustained attention is
followed by decline in planning and rule learning/shifting,
and occurs before behavioral symptoms as reported by
informants. These results help to clarify uncertainties
about the sequence of events and staging of AD in DS.
Future work including longitudinal data in such models
will improve our understanding of decline due to AD in
DS further, and will help to improve dementia diagnosis,
as well as to inform selection of cognitive outcome mea-
sures in future clinical trials to prevent or delay the devel-
opment of dementia during the prodromal period.
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